BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 22516053)

  • 1. Selective purging of human multiple myeloma cells from autologous stem cell transplantation grafts using oncolytic myxoma virus.
    Bartee E; Chan WM; Moreb JS; Cogle CR; McFadden G
    Biol Blood Marrow Transplant; 2012 Oct; 18(10):1540-51. PubMed ID: 22516053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncolytic viral purging of leukemic hematopoietic stem and progenitor cells with Myxoma virus.
    Rahman MM; Madlambayan GJ; Cogle CR; McFadden G
    Cytokine Growth Factor Rev; 2010; 21(2-3):169-75. PubMed ID: 20211576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transplantation of autologous bone marrow pre-loaded
    Villa NY; Rahman MM; Mamola J; Sharik ME; de Matos AL; Kilbourne J; Lowe K; Daggett-Vondras J; D'Isabella J; Goras E; Chesi M; Bergsagel PL; McFadden G
    Oncotarget; 2022; 13():490-504. PubMed ID: 35251496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clonotypic myeloma cells able to xenograft myeloma to nonobese diabetic severe combined immunodeficient mice copurify with CD34 (+) hematopoietic progenitors.
    Pilarski LM; Belch AR
    Clin Cancer Res; 2002 Oct; 8(10):3198-204. PubMed ID: 12374689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ex vivo virotherapy with myxoma virus does not impair hematopoietic stem and progenitor cells.
    Villa NY; Bais S; Chan WM; Meacham AM; Wise E; Rahman MM; Moreb JS; Rosenau EH; Wingard JR; McFadden G; Cogle CR
    Cytotherapy; 2016 Mar; 18(3):465-80. PubMed ID: 26857235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ex vivo graft purging and expansion of autologous blood progenitor cell products from patients with multiple myeloma.
    Yang H; Robinson SN; Nieto Y; Jones RJ; Gocke CD; Lu J; Giralt SA; Jones RB; Decker WK; Xing D; Steiner D; Champlin RE; McMannis JD; Ng J; Thomas MW; Shah N; Andersson BS; Parmar S; Shpall EJ
    Cancer Res; 2011 Jul; 71(14):5040-9. PubMed ID: 21646477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myxoma virus suppresses proliferation of activated T lymphocytes yet permits oncolytic virus transfer to cancer cells.
    Villa NY; Wasserfall CH; Meacham AM; Wise E; Chan W; Wingard JR; McFadden G; Cogle CR
    Blood; 2015 Jun; 125(24):3778-88. PubMed ID: 25904246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Shiga-like toxin-1 receptor on human breast cancer, lymphoma, and myeloma and absence from CD34(+) hematopoietic stem cells: implications for ex vivo tumor purging and autologous stem cell transplantation.
    LaCasse EC; Bray MR; Patterson B; Lim WM; Perampalam S; Radvanyi LG; Keating A; Stewart AK; Buckstein R; Sandhu JS; Miller N; Banerjee D; Singh D; Belch AR; Pilarski LM; Gariépy J
    Blood; 1999 Oct; 94(8):2901-10. PubMed ID: 10515895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reovirus oncolysis as a novel purging strategy for autologous stem cell transplantation.
    Thirukkumaran CM; Luider JM; Stewart DA; Cheng T; Lupichuk SM; Nodwell MJ; Russell JA; Auer IA; Morris DG
    Blood; 2003 Jul; 102(1):377-87. PubMed ID: 12637331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic therapy with oncolytic myxoma virus cures established residual multiple myeloma in mice.
    Bartee E; Bartee MY; Bogen B; Yu XZ
    Mol Ther Oncolytics; 2016; 3():16032. PubMed ID: 27933316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Positive selection of autologous peripheral blood stem cells.
    Lopez M; Beaujean F
    Baillieres Best Pract Res Clin Haematol; 1999; 12(1-2):71-86. PubMed ID: 11000984
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multicenter phase III trial to evaluate CD34(+) selected versus unselected autologous peripheral blood progenitor cell transplantation in multiple myeloma.
    Vescio R; Schiller G; Stewart AK; Ballester O; Noga S; Rugo H; Freytes C; Stadtmauer E; Tarantolo S; Sahebi F; Stiff P; Meharchard J; Schlossman R; Brown R; Tully H; Benyunes M; Jacobs C; Berenson R; DiPersio J; Anderson K; Berenson J
    Blood; 1999 Mar; 93(6):1858-68. PubMed ID: 10068658
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paclitaxel-Fe3O4 nanoparticles inhibit growth of CD138(-) CD34(-) tumor stem-like cells in multiple myeloma-bearing mice.
    Yang C; Wang J; Chen D; Chen J; Xiong F; Zhang H; Zhang Y; Gu N; Dou J
    Int J Nanomedicine; 2013; 8():1439-49. PubMed ID: 23610522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cotransplantation of ex vivo expanded and unexpanded cord blood units in immunodeficient mice using insulin growth factor binding protein-2-augmented mesenchymal cell cocultures.
    Ong LM; Fan X; Chu PP; Gay FP; Bari S; Ang JM; Li Z; Chen J; Lim SK; Bunte RM; Hwang WY
    Biol Blood Marrow Transplant; 2012 May; 18(5):674-82. PubMed ID: 22240732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myeloma progenitors in the blood of patients with aggressive or minimal disease: engraftment and self-renewal of primary human myeloma in the bone marrow of NOD SCID mice.
    Pilarski LM; Hipperson G; Seeberger K; Pruski E; Coupland RW; Belch AR
    Blood; 2000 Feb; 95(3):1056-65. PubMed ID: 10648422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transplantation with selected autologous peripheral blood CD34+Thy1+ hematopoietic stem cells (HSCs) in multiple myeloma: impact of HSC dose on engraftment, safety, and immune reconstitution.
    Michallet M; Philip T; Philip I; Godinot H; Sebban C; Salles G; Thiebaut A; Biron P; Lopez F; Mazars P; Roubi N; Leemhuis T; Hanania E; Reading C; Fine G; Atkinson K; Juttner C; Coiffier B; Fière D; Archimbaud E
    Exp Hematol; 2000 Jul; 28(7):858-70. PubMed ID: 10907648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Virotherapy using myxoma virus prevents lethal graft-versus-host disease following xeno-transplantation with primary human hematopoietic stem cells.
    Bartee E; Meacham A; Wise E; Cogle CR; McFadden G
    PLoS One; 2012; 7(8):e43298. PubMed ID: 22905251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficient and nontoxic adenoviral purging method for autologous transplantation in breast cancer patients.
    Lillo R; Ramírez M; Alvarez A; Santos S; García-Castro J; Fernández de Velasco J; Avilés MJ; Gómez-Pineda A; Díez JL; Balas A; Vicario JL; Bueren JA; García-Sánchez F
    Cancer Res; 2002 Sep; 62(17):5013-8. PubMed ID: 12208755
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD34+ hematopoietic progenitor cell dose as a predictor of engraftment and survival in multiple myeloma patients undergoing autologous stem cell transplantation.
    Aladağ Karakulak E; Demiroğlu H; Büyükaşik Y; Turgut M; Aksu S; Sayinalp N; Haznedaroğlu IC; Özcebe OI; Göker H
    Turk J Med Sci; 2020 Dec; 50(8):1851-1856. PubMed ID: 32512672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ex Vivo Expansion of CD34
    Bari S; Zhong Q; Fan X; Poon Z; Lim AST; Lim TH; Dighe N; Li S; Chiu GNC; Chai CLL; Hwang WYK
    Stem Cells Transl Med; 2018 May; 7(5):376-393. PubMed ID: 29392885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.